Clinical Trial Update: Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of radiotherapy and gefitinib (Iressa) in EGFR mutation-positive locally advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: ZhuGuangYing | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN